Rani Therapeutics Holdings, Inc. (RANI) News

Rani Therapeutics Holdings, Inc. (RANI): $18.52

-1.74 (-8.59%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add RANI to Watchlist
Sign Up

Industry: Biotech


Ranked

of 509

in industry

Filter RANI News Items

RANI News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

RANI News Highlights

  • For RANI, its 30 day story count is now at 3.
  • Over the past 15 days, the trend for RANI's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about RANI are GAME.

Latest RANI News From Around the Web

Below are the latest news stories about Rani Therapeutics Holdings Inc that investors may wish to consider to help them evaluate RANI as an investment opportunity.

Most of this year's flood of new Bay Area public companies are 'under water'

Seventy-two Bay Area companies have gone public this year. But only 29 have increased in value since their debut.

Yahoo | October 8, 2021

This Recent Biologics IPO Could Be Heading Toward a Gain of 60% or More

A game-changing pill from Rani Therapeutics may offer an easier alternative to fight debilitating diseases.

Yahoo | October 4, 2021

Rani Therapeutics to Present at Cantor Fitzgerald Virtual Global Healthcare Conference

SAN JOSE, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today announced that the company’s Chief Executive Officer, Talat Imran, will present at the Cantor Fitzgerald Virtual Global Healthcare Conference on Thursday, September 30, 2021, at 9:00 a.m. PT / 12:00 p.m. ET. Interested parties can access the live audio webcast for this conference from the Events page in the Investor Relat

Yahoo | September 23, 2021

Rani Therapeutics Reports Second Quarter 2021 Financial Results, Provides Corporate Update

- IPO in July 2021 raised $84.3 million in gross proceeds -- Talat Imran Appointed Chief Executive Officer -- Enhanced leadership team with key management and board of directors’ appointments - SAN JOSE, Calif., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today reported financial results for the second quarter ended June 30, 2021 and provided

Yahoo | September 13, 2021

Rani Therapeutics Announces Appointment of Eric Groen as General Counsel

SAN JOSE, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics, today announced the appointment of Eric Groen as General Counsel. Mr. Groen has more than 25 years of experience managing legal matters in corporate and private practice. “Eric is an accomplished executive whose legal expertise and

Yahoo | September 9, 2021

Rani Therapeutics, RxSight: 2 Bullish Health Care Stock Picks From BofA

Rani Therapeutics Holdings, Inc. (NASDAQ: RANI), an early stage platform technology company that promotes oral dosing with its RaniPill, and RxSight, Inc. (NASDAQ: RXST), an ophthalmology-focused MedTech company, went public in late July. Here's what BofA Securities has to say about the newly listed stocks. The Healthcare Analysts: BofA Securities analyst Geoff Meacham initiated coverage of Rani with a Buy rating and $23 price target. Bob Hopkins from BofA initiated coverage of RxSight with a Bu

Yahoo | August 24, 2021

Rani Therapeutics Announces Closing of its Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

SAN JOSE, Calif., Aug. 13, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq:RANI) (“Rani Therapeutics” or “Rani”), a clinical stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics today announced the final closing of its initial public offering of 7,666,667 shares of its Class A common stock, which includes 1,000,000 shares sold pursuant to the full exercise by the underwriters of their option to purchase addit

Yahoo | August 13, 2021

Rani Therapeutics Announces Pricing of Initial Public Offering

SAN JOSE, Calif., July 30, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”), a clinical stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics, today announced the pricing of its initial public offering of 6,666,667 shares of Class A common stock at a price to the public of $11.00 per share. The gross proceeds to Rani from the offering, before deducting underwriting discounts and commissi

Yahoo | July 30, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6579 seconds.